Results 151 to 160 of about 9,825 (240)
Broad Skills, Smaller Footprints? Generalist CEOs and Firm Biodiversity Exposure
ABSTRACT We examine whether CEO generalist skills predict firm‐level biodiversity risk exposure, an emerging strategic and financial concern. Using the biodiversity indicator developed based on textual analysis and the General Ability Index, we find that firms led by generalist CEOs are associated with significantly lower disclosed biodiversity risk ...
Hafiz Hoque +2 more
wiley +1 more source
The therapeutic effects of labetalol in chronic stress- and immuno-agonist-induced cough hypersensitivity and lung inflammation involve reducing interferon-γ-producing T lymphocytes. [PDF]
Song T +7 more
europepmc +1 more source
Status and future of recombinant adeno‐associated virus vector manufacturing
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley +1 more source
Targeting Inflammatory and Oxidative Pathways in Idiopathic Pulmonary Fibrosis: Synergistic Effects of Quercetin and Pirfenidone in Modulating Nrf2/PPAR-γ and TLR-4/NF-κB Pathways. [PDF]
Wanas H +8 more
europepmc +1 more source
High‐throughput anion‐exchange chromatography process development enables scalable purification of high‐purity recombinant adeno‐associated virus capsids. Abstract Recombinant adeno‐associated virus (rAAV) production commonly yields a high proportion of empty and partially filled capsids, necessitating downstream purification to enrich full capsids ...
Kevin Vera +8 more
wiley +1 more source
A Contemporary Review of Subcutaneous and Extravascular Implantable Cardiac Defibrillators. [PDF]
Jalil A +5 more
europepmc +1 more source
ABSTRACT Background In the REFORM trial, treatment of coronary in‐stent restenosis with a Biolimus A9™ drug‐coated balloon (BCB) was found to be inferior with respect to in‐segment percentage stenosis at 6‐months in comparison to treatment with a standard paclitaxel coated paclitaxel‐coated balloon (PCB). Aims In this manuscript, the final prespecified
Daniel O'Callaghan +18 more
wiley +1 more source
Analysis of symptomatic brain aneurysms with three-dimensional aneurysm wall enhancement. [PDF]
Zhu C +18 more
europepmc +1 more source

